{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:45:32Z","timestamp":1751564732842},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Epidemiologie und Klinik\u2002Die im Rahmen der COVID-19-Pandemie ergriffenen Infektionsschutzma\u00dfnahmen und Reisebeschr\u00e4nkungen haben auch die \u00dcbertragung saisonaler Influenzaviren stark eingeschr\u00e4nkt. Es muss jedoch davon ausgegangen werden, dass das Infektionsgeschehen in der kommenden Influenzasaison nach dem Wegfall dieser Ma\u00dfnahmen wieder zunehmen wird. Koinfektionen von saisonalen Influenzaviren und SARS-CoV-2 sind m\u00f6glich und gehen gegebenenfalls mit einem erh\u00f6hten Risiko f\u00fcr schwere Krankheitsverl\u00e4ufe einher.<\/jats:p><jats:p>\n          Influenza-Impfung\u2002Die STIKO empfiehlt seit 2021 ab einem Alter von 60 Jahren den Einsatz tetravalenter Hochdosis-Impfstoffe. Diese enthalten im Vergleich zu standarddosierten Impfstoffen die 4-fache Antigenmenge. Impfstoffe, die auf der mRNA-Technologie beruhen, sowie universelle Influenza-Impfstoffe befinden sich in klinischer Pr\u00fcfung. Es besteht nun auch f\u00fcr Apotheker*innen die M\u00f6glichkeit, Grippeimpfungen unter bestimmten Auflagen durchzuf\u00fchren.<\/jats:p><jats:p>\n          Therapie\u2002F\u00fcr Patient*innen mit erh\u00f6htem Risiko f\u00fcr einen schweren Verlauf wird weiterhin eine fr\u00fchzeitige antivirale Therapie mit dem Neuraminidase-Inhibitor Oseltamivir empfohlen. Der Gemeinsame Bundesausschuss (G-BA) sieht f\u00fcr Baloxavir marboxil dagegen keinen Zusatznutzen hinsichtlich der Therapie der Influenzavirus-Infektion. Die aktuelle S3-Leitlinie \u201eBehandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie\u201c gibt eine moderate Empfehlung zur antibakteriellen Behandlung hospitalisierter Patient*innen mit Influenza-Nachweis und nachgewiesenen pulmonalen Infiltraten. Der Grund daf\u00fcr ist, dass eine bakterielle Superinfektion auch bei fehlendem mikrobiologischem Nachweis nicht ausgeschlossen werden kann und diese mit erh\u00f6hter Letalit\u00e4t einher geht.<\/jats:p>","DOI":"10.1055\/a-1838-9223","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T23:40:51Z","timestamp":1667346051000},"page":"1456-1464","source":"Crossref","is-referenced-by-count":2,"title":["Saisonale Influenza \u2013 Aktuelles zu Epidemiologie, Pr\u00e4vention und Therapie"],"prefix":"10.1055","volume":"147","author":[{"given":"Thomas Theo","family":"Brehm","sequence":"additional","affiliation":[{"name":"I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Hamburg-Eppendorf"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Hennigs","sequence":"additional","affiliation":[{"name":"I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Hamburg-Eppendorf"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2018.23.16.17-00454","article-title":"Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013","volume":"23","author":"A Cassini","year":"2018","journal-title":"Euro Surveill"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41467-022-29402-5","article-title":"Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination","volume":"13","author":"V Dhanasekaran","year":"2022","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/s0140-6736(22)00383-x","article-title":"SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses","volume":"399","author":"M C Swets","year":"2022","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7326\/m21-3668","article-title":"Characteristics and Outcomes of Hospitalized Pregnant Women With Influenza, 2010 to 2019: A Repeated Cross-Sectional Study","volume":"175","author":"R Holstein","year":"2022","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/978-3-540-92165-3_20","article-title":"Immunosenescence and influenza vaccine efficacy","volume":"333","author":"S Sambhara","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"C A DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1080\/21645515.2021.1983387","article-title":"Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial","volume":"17","author":"S Pepin","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/d41573-021-00176-7","article-title":"mRNA flu shots move into trials","volume":"20","author":"E Dolgin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"R A Feldman","year":"2019","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","article-title":"Broadly neutralizing antibodies target a haemagglutinin anchor epitope","volume":"602","author":"J J Guthmiller","year":"2022","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"R Nachbagauer","year":"2021","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00024-x","article-title":"Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1\u20132 randomised controlled trial","author":"N Folschweiller","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-med-120617-041310","article-title":"Is a Universal Influenza Virus Vaccine Possible?","volume":"71","author":"R Nachbagauer","year":"2020","journal-title":"Annu Rev Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.7326\/l21-0018","article-title":"Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults","volume":"174","author":"E J Chow","year":"2021","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/circulationaha.121.057042","article-title":"Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial","volume":"144","author":"O Fr\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2119151","DOI":"10.1001\/jamanetworkopen.2021.19151","article-title":"Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis","volume":"4","author":"J W Liu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1055\/a-1497-0693","article-title":"[Management of Adult Community-Acquired Pneumonia and Prevention \u2013 Update 2021]","volume":"75","author":"S Ewig","year":"2021","journal-title":"Pneumologie"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1183\/09031936.00037410","article-title":"How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia","volume":"37","author":"H von Baum","year":"2011","journal-title":"Eur Respir J"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1838-9223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T23:41:18Z","timestamp":1667346078000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1838-9223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":18,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11,1]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1838-9223","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}